Navigation Links
New Transgenic Mushrooms Raise Hope for Mass Production of Human Drugs

Penn State and Agariger, Inc. have patented the technology of making new transgenic mushrooms, which have increased hope of using mushrooms for the mass production of commercially valuable proteins or useful human drugs.

The technology was introduced by a team of researchers including Charles Peter Romaine and Xi Chen at Penn State.

As part of the study, scientists developed a technique to genetically modify Agaricus bisporus, which is the predominant edible species worldwide by attaching a gene that confers resistance to hygromycin, an antibiotic, to circular pieces of bacterial DNA called plasmids, which have the ability to multiply within a bacterium known as Agrobacterium.

The hygromycin resistance gene was a marker gene to help sort out the transgenic mushroom cells from the non-transgenic cells.

Scientists then cut small pieces off the mushroom's gill tissue and added it to a flask containing the altered bacterium. Over the course of several days, as the bacterium went through its lifecycle, it transferred a portion of its plasmid into the mushroom cell, and integrated the introduced gene into the chromosome of the mushroom.

The researchers then exposed the mushroom cells to hygromycin. The antibiotic killed all the normal cells, separating out those that had been genetically altered for resistance.

The study demonstrated that if a second gene, insulin for example, were to be patched in the plasmid, that gene would be expressed as well.

"There is a high probability that if the mushroom cell has the hygromycin resistance gene, it will also have the partner gene," Romaine said.

Researchers noted that the process of producing biopharmaceuticals is potentially faster and cheaper with mushrooms than conventional technologies.

"With mushrooms, we can use commercial technology to convert the vegetative tissue from mushroom strains stored in t
'"/>




Page: 1 2

Related medicine news :

1. Goat’s Milk One of the First Transgenic Food That Benefits Human
2. Mushrooms can help fight chronic disease
3. Novel Vitamin D source in Mushrooms!
4. Mushrooms are Rich Source of Antioxidants
5. Four of Family Died After Consuming Poisonous Mushrooms
6. Magic Mushrooms Treat Obsessive Compulsion Disorder
7. Heavy Drinking Raises Risk of Liver Cancer
8. Swimming in Chlorinated Pools Raises Asthma Risk
9. New Treatment To Raise Good Cholesterol
10. Common Infections Found To Raise An Individuals Risk Of Having A Heart Attack Or Stroke
11. Polycystic Ovary In Women May Raise Liver Disease
Post Your Comments:
(Date:5/11/2008)...e/ -- As the global community observes,the destruc...yclone of all,time and the associated mounting fru... victims, the Alumni Myanmar Institutes of Medicin...importantly, successful-in initiating,medical care...000 people,are assumed dead. AMIMA has funded the ...
(Date:5/11/2008)... -- The winners of today,s Susan G.,Komen Pittsbur...ace Overall Winners Male: Pat McGuire, Charl...bein, Pittsburgh, Pa., 19:19, 2nd Place Overall W...: Anna Beck, Washington, Pa., 19:22, 3rd Place O..., Pa., 16:13 Female: Jessica Winter, Pittsbu...
(Date:5/11/2008)...nd for Unveiling of the New Name of the ...HICAGO, May 11 /PRNewswire/ -- Thousands of people...ntry were present for the unveiling of the,new nam...t cancer,organization, This year, Y-ME National B...h anniversary. In celebration of this landmark, Y-...
(Date:5/10/2008)...orts to Gain Clearance for Airlift of ... May 10 /PRNewswire-USNewswire/ -- An AmeriCares,e...today to assess the,crisis situation and continue ...ion,s airlift of 15 tons of essential medicines an...king closely with the World Health Organization to...
Breaking Medicine News(10 mins):Health News:Alumni Myanmar Institutes of Medicine Association (AMIMA) Races Time to Help Cyclone Victims 2Health News:16th Annual Komen Pittsburgh Race for the Cure(R) Winners Announced 2Health News:Y-ME Makes Historic Announcement on Mother's Day 2Health News:Y-ME Makes Historic Announcement on Mother's Day 3Health News:AmeriCares Relief Worker Arrives in Myanmar 2
... government announced plans on Thursday to ban all... of the clitoris which just days ago cost the lif... which affects both Muslim and Christian women in ...he pharaohs, was banned in 1997 but doctors were a...
...alth Organization (WHO) has said that the risk of ...tely doubles after travel of four hours or more. ...the WHO, however, says that the absolute risk of d...d and immobile for more than four hours remains re...
...surgical students stick themselves with needles an... resulting injuries could be infectious and very ...a new study by reported Martin Makary, M.D., a sur...s Hospital, and colleagues, in the June 28 issue o...
...ls, a leading healthcare provider in Andhra Prades...llion during the next one year to set up new stat...are brand, which has just completed 10 years, plan... in Madhya Pradesh, Maharashtra, Chhattisgarh, Guj...
Other Medicine News:Health News:Egypt Outlaws All Female Circumcision 2Health News:Thrombosis Risk in Travel Lasting Over Four Hours is Higher: WHO 2Health News:Surgical Students Fail to Report Needle Stick Injuries 2Health News:Surgical Students Fail to Report Needle Stick Injuries 3
(Date:5/8/2008)...Call/ -- DATATRAK International, Inc.,(Nasdaq: DA... global,eClinical solutions for the clinical trial...or the first quarter of 2008., For the three mont...mately 41% to $2,088,000 and the Company reported ...n both a basic and diluted basis. These,results co...
(Date:5/8/2008)...tial of asenapine in the treatment of ...GTON, May 8 /- Schering-Plo... an overview of asenapine clinical trials,from the... Meeting of the,American Psychiatric Association i..., involving patients with bipolar I disorder and s...
(Date:5/8/2008)...e-FirstCall/ -- VION PHARMACEUTICALS,INC. (Nasdaq...ator-sponsored,Phase I/II clinical trial of its le...combination with cytarabine in elderly patients wi... (AML) and high-risk,myelodysplastic syndromes (MD...on of Ellen K. Ritchie, M.D. at The Weill-Cornell ...
(Date:5/8/2008)...e-FirstCall/ -- AstraZeneca (NYSE:,AZN) today anno...plication,(sNDA) to the U.S. Food and Drug Adminis...rate) Extended-Release Tablets to seek approval fo...AD), including maintenance of,antianxiety effect. ...an,atypical antipsychotic medicine in GAD. The sub...
Breaking Medicine Technology:DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Purdue research finds similarities in dog human breast cancer pre malignant lesions 1245 1Purdue research finds similarities in dog human breast cancer pre malignant lesions 1245 2Purdue research finds similarities in dog human breast cancer pre malignant lesions 1245 3Purdue research finds similarities in dog human breast cancer pre malignant lesions 1245 4More Black Children Dying From Diabetes 6447 1More Black Children Dying From Diabetes 6447 2More Black Children Dying From Diabetes 6447 3Carnegie Mellon neuroscientist proposes new theory of brain flexibility 6442 1Carnegie Mellon neuroscientist proposes new theory of brain flexibility 6442 2Carnegie Mellon neuroscientist proposes new theory of brain flexibility 6442 3TriWest Executive Advisory Board Marks Its Fifth Year 6438 1TriWest Executive Advisory Board Marks Its Fifth Year 6438 2TriWest Executive Advisory Board Marks Its Fifth Year 6438 3
...O, Calif., May 02, 2007 /PRNewswire/ -- Ceregene, ...Phase 1 trial of,CERE-110, a gene therapy product ...the treatment of Alzheimer,s disease. After one,ye...who received,CERE-110 in the trial indicate that a...erated, and an interim analysis suggested that,the...
....C.--(BUSINESS WIRE)--May 4, 2007 - Argos Therapeu...he immunosuppressive,properties of soluble CD83 at...eld in San Francisco, May 5-9. The presentations,w...e University of,Western Ontario., "These data sugg...ival in transplantation, and that it can also act,...
Other Medicine Technology:Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 2Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 3Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 4Argos Therapeutics Presents Immunosuppression Data for Soluble CD83,at the American Society of Transplantation Congress 2007 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: